COMPANY
AlphaRose Therapeutics
Connect
See your connections at AlphaRose Therapeutics on LinkedIn (search by name, results not checked)
Funding and NIH signals
- NIH award NIH awarded $313K (SBIR Phase II 1R44HD122555-01, new, notice Sep 17, 2026). NIH RePORTER 1R44HD122555-01 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R44HD122555-01
Organization: ALPHAROSE THERAPEUTICS INC.; City/State: Leander, TX; Project number: 1R44HD122555-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 313208; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder.; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44HD122555-01